Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
CYRX - CryoPort, Inc.
Market Cap 687.73M P/E - EPS this Y 41.20% Ern Qtrly Grth -
Income -107.59M Forward P/E -18.41 EPS next Y 23.10% 50D Avg Chg -17.00%
Sales 233.26M PEG - EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 1.36 EPS next 5Y - 52W High Chg -67.00%
Recommedations 2.30 Quick Ratio 10.94 Shares Outstanding 49.16M 52W Low Chg 9.00%
Insider Own 2.42% ROA -3.67% Shares Float 44.46M Beta 1.59
Inst Own 107.16% ROE -19.06% Shares Shorted/Prior 4.43M/4.17M Price 15.10
Gross Margin 42.59% Profit Margin -42.69% Avg. Volume 618,808 Target Price 18.33
Oper. Margin -34.34% Earnings Date May 2 Volume 401,169 Change -3.82%
Industrials | Integrated Freight & Logistics | United States
About CryoPort, Inc.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

CryoPort, Inc. News
04/25/24 Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
03/15/24 Analysts Are Updating Their Cryoport, Inc. (NASDAQ:CYRX) Estimates After Its Full-Year Results
03/14/24 Cryoport Full Year 2023 Earnings: EPS Misses Expectations
03/13/24 Cryoport, Inc. (NASDAQ:CYRX) Q4 2023 Earnings Call Transcript
03/12/24 CryoPort Inc (CYRX) Reports Mixed Financial Results Amidst Global Challenges
03/12/24 CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
03/12/24 Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
02/27/24 Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
02/15/24 Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
02/13/24 Should You Buy CryoPort, Inc. (CYRX) After Golden Cross?
02/03/24 Shareholders in Cryoport (NASDAQ:CYRX) are in the red if they invested three years ago
11/27/23 Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services
11/16/23 Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express
11/14/23 At US$11.25, Is It Time To Put Cryoport, Inc. (NASDAQ:CYRX) On Your Watch List?
11/09/23 Cryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call Transcript
11/08/23 CryoPort Inc (CYRX) Faces Economic Headwinds but Sees Growth in Key Segments
11/08/23 Cryoport Reports Third Quarter 2023 Financial Results
11/02/23 Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition
10/25/23 Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023
10/12/23 Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF
CYRX Chatroom

User Image H73 Posted - 1 week ago

$CYRX new markets can't be waiting for the FDA https://bioedge.org/stem-cells/utahs-new-stem-cell-law-undermines-fdas-authority/

User Image GakiYoui_Atsu Posted - 2 weeks ago

$AEVA Aeva Technologies, Inc. (NYSE:AEVA) Receives $2.29 Average Target Price from Analysts $JAZZ Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $190.70 $LNC Brokerages Set Lincoln National Co. (NYSE:LNC) Target Price at $26.20 $CYRX Needham & Company LLC Trims Cryoport (NASDAQ:CYRX) Target Price to $18.00 $WIMI Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud(NASDAQ: WIMI)

User Image H73 Posted - 2 weeks ago

$CYRX client expanded use ...The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

User Image H73 Posted - 2 weeks ago

$CYRX abecma expanded line. FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

User Image DonCorleone77 Posted - 3 weeks ago

$CYRX Cryoport assumed with a Buy at Jefferies Jefferies assumed coverage of Cryoport with a Buy rating and price target of $21, up from $17. As a leader in cryogenic cold-chain logistics, Cryoport is compelling play on the industry, with commercially supported therapies and a pipeline of clinical trials offering long-duration revenue streams, the analyst tells investors in a research note.

User Image AdiDasRom Posted - 3 weeks ago

$CYRX go go go

User Image R33dh Posted - 3 weeks ago

$CYRX Go go go!

User Image Gmoney305 Posted - 03/28/24

$CYRX

User Image AdiDasRom Posted - 03/27/24

$CYRX

User Image insiderbuyingselling Posted - 4 weeks ago

$CYRX new insider selling: 1079 shares. http://insiderbuyingselling.com/?t=CYRX

User Image H73 Posted - 4 weeks ago

$CYRX looking about set to bolt into the 20's

User Image H73 Posted - 4 weeks ago

$CYRX United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD). Cryoport client to submit NDA next week. Patient population is about 2000+ annually I believe.

User Image H73 Posted - 1 month ago

$CYRX fill the 19.40 gap this run ?

User Image DueDilly102 Posted - 1 month ago

$CYRX Keep it up G, you're doing great!

User Image AdiDasRom Posted - 1 month ago

$CYRX Bullish

User Image H73 Posted - 1 month ago

$CYRX the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor of Abecma’s (idecabtagene vicleucel) benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM). sNDA later this year.

User Image R33dh Posted - 1 month ago

$CYRX https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma

User Image insiderbuyingselling Posted - 1 month ago

$CYRX new insider selling: 2730 shares. http://insiderbuyingselling.com/?t=CYRX

User Image Gmoney305 Posted - 1 month ago

$CYRX funds love to play with this

User Image Gmoney305 Posted - 1 month ago

$CYRX

User Image H73 Posted - 1 month ago

$CYRX cyrx customer Orchard Therapeutics Receives FDA Approval of Lenmeldy™. Very small population.

User Image NakadasuTellaria Posted - 1 month ago

$WIMI: Evaluate Research reiterated a "buy" rating with $7 latest price target for WIMI Hologram Cloud $AEVA Aeva Technologies, Inc. (NYSE:AEVA) Receives $2.29 Average Target Price from Analysts $JAZZ Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $190.70 $LNC Brokerages Set Lincoln National Co. (NYSE:LNC) Target Price at $26.20 $CYRX Needham & Company LLC Trims Cryoport (NASDAQ:CYRX) Target Price to $18.00

User Image H73 Posted - 1 month ago

$CYRX cyrx customer BMS Breyanzi gets another expanded indication

User Image erevnon Posted - 1 month ago

UBS maintains CryoPort $CYRX at Neutral and raises the price target from $14.5 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Gmoney305 Posted - 1 month ago

$CYRX Stephens & Co. Reiterates Equal-Weight on CryoPort, Maintains $17 Price Target ...clowns try 10 bucks

User Image Thestocktraderhubzee Posted - 1 month ago

WATCHLIST MAR 14 2024.. $CLNN HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target $NXST Rosenblatt Maintains Buy on Nexstar Media Gr, Lowers Price Target to $213 $BLDP Raymond James Maintains Market Perform on Ballard Power Systems, Lowers Price Target to $4 $GDYN Cantor Fitzgerald Maintains Overweight on Grid Dynamics Holdings, Raises Price Target to $17 $CYRX Stephens & Co. Reiterates Equal-Weight on CryoPort, Maintains $17 Price Target

User Image wrynot Posted - 1 month ago

$CYRX Jerry…it’s time to sell. Whose idea was it to buy a refrigeration company? That’s low margin GE stuff.

User Image erevnon Posted - 1 month ago

Stephens & Co. reiterates CryoPort $CYRX at Equal-Weight and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Gmoney305 Posted - 1 month ago

$CYRX

User Image DonCorleone77 Posted - 1 month ago

$CYRX Cryoport ssees FY24 revenue $242M-$252M, consensus $253.22M The Company is expecting revenue to grow progressively.

Analyst Ratings
UBS Neutral Mar 15, 24
Stephens & Co. Equal-Weight Mar 13, 24
Needham Buy Mar 13, 24
Needham Buy Jan 18, 24
Morgan Stanley Equal-Weight Aug 17, 23
Needham Buy Aug 10, 23
UBS Neutral Jul 18, 23
Stephens & Co. Equal-Weight Jul 17, 23
Keybanc Sector Weight Jul 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hariri Robert J Director Director Dec 14 Sell 16.89 800 13,512 12,716 12/18/23
Hariri Robert J Director Director Dec 11 Sell 15.50 1,000 15,500 13,516 12/13/23
Hariri Robert J Director Director Sep 06 Sell 13.60 1,500 20,400 14,516 09/12/23
SHELTON JERRELL See Remarks See Remarks Sep 01 Sell 14.27 26,875 383,506 632,424 09/05/23
SHELTON JERRELL See Remarks See Remarks Sep 01 Option 1.87 54,000 100,980 659,299 09/05/23
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Aug 29 Option 3.07 16,000 49,120 123,150 08/30/23
BERMAN RICHARD J Director Director May 11 Sell 21.5058 7,203 154,906 100,000 05/12/23
SHELTON JERRELL President, CEO President, CEO May 10 Sell 21.63 141,159 3,053,269 605,299 05/12/23
SHELTON JERRELL President, CEO President, CEO May 10 Option 3.24 286,377 927,861 746,458 05/12/23
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer May 10 Sell 21.94 19,918 437,001 107,150 05/12/23
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer May 10 Option 3.24 19,918 64,534 127,068 05/12/23
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Mar 09 Sell 20.14 1,159 23,342 97,764 03/13/23
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Mar 09 Option 0 2,667 98,923 03/13/23
Sawicki Mark W Chief Scientific Off.. Chief Scientific Officer Mar 09 Sell 20.14 1,476 29,727 63,032 03/13/23
Sawicki Mark W Chief Scientific Off.. Chief Scientific Officer Mar 09 Option 0 2,667 64,508 03/13/23
SHELTON JERRELL Chief Executive Offi.. Chief Executive Officer Mar 09 Sell 20.14 3,798 76,492 435,588 03/13/23
SHELTON JERRELL Chief Executive Offi.. Chief Executive Officer Mar 09 Option 0 8,250 439,386 03/13/23
BERMAN RICHARD J Director Director Dec 01 Sell 19.6298 7,250 142,316 12/05/22
BERMAN RICHARD J Director Director Aug 16 Sell 43.0533 2,708 116,588 107,203 08/16/22
Hariri Robert J Director Director Aug 11 Sell 43.2907 2,000 86,581 7,911 08/16/22
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Mar 09 Option 0 2,667 86,896 03/11/22
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Mar 09 Sell 31.05 1,095 34,000 85,801 03/11/22
SHELTON JERRELL Chief Executive Offi.. Chief Executive Officer Mar 09 Sell 31.05 3,298 102,403 404,044 03/11/22
SHELTON JERRELL Chief Executive Offi.. Chief Executive Officer Mar 09 Option 0 8,250 407,342 03/11/22
Sawicki Mark W Chief Scientific Off.. Chief Scientific Officer Mar 09 Option 0 2,667 52,796 03/11/22
Sawicki Mark W Chief Scientific Off.. Chief Scientific Officer Mar 09 Sell 31.05 1,410 43,780 51,386 03/11/22
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Jan 27 Option 3.52 52,812 185,898 84,229 01/31/22
SHELTON JERRELL President, CEO President, CEO Nov 10 Option 2.34 65,250 152,685 629,342 11/12/21
SHELTON JERRELL President, CEO President, CEO Nov 10 Sell 79.29 65,250 5,173,672 564,092 11/12/21
HANCOCK DANIEL M Director Director Oct 20 Option 14.35 15,000 215,250 15,844 10/22/21
HANCOCK DANIEL M Director Director Oct 20 Sell 75.57 15,000 1,133,550 4,627 10/22/21
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Oct 14 Option 7.8 49,918 389,360 81,335 10/15/21
STEFANOVICH ROBERT Chief Financial Offi.. Chief Financial Officer Oct 14 Sell 67.99 49,918 3,393,925 31,417 10/15/21
BERMAN RICHARD J Director Director Sep 15 Option 16.19 25,000 404,750 125,000 09/15/21
BERMAN RICHARD J Director Director Sep 15 Sell 63.78 25,000 1,594,500 100,000 09/15/21
HANCOCK DANIEL M Director Director Jun 23 Option 9.73 12,850 125,030 17,477 06/23/21
HANCOCK DANIEL M Director Director Jun 23 Sell 65.78 12,850 845,273 4,627 06/23/21
HANCOCK DANIEL M Director Director Jun 09 Option 9.73 20,000 194,600 14,627 06/09/21
HANCOCK DANIEL M Director Director Jun 09 Sell 60.63 20,000 1,212,600 4,627 06/09/21
ZECCHINI EDWARD J Director Director Apr 09 Option 4.8 5,417 26,002 5,417 04/09/21
ZECCHINI EDWARD J Director Director Apr 09 Sell 52.05 5,417 281,955 04/09/21
BERMAN RICHARD J Director Director Apr 09 Option 11.82 27,789 328,466 100,000 04/09/21
BERMAN RICHARD J Director Director Mar 25 Option 7.3 51,129 373,242 72,211 03/25/21
SHELTON JERRELL President, CEO President, CEO Dec 30 Option 6.83 91,560 625,355 493,156 12/30/20
BERMAN RICHARD J Director Director Nov 13 Option 3.82 20,000 76,400 20,000 11/13/20
BERMAN RICHARD J Director Director Nov 13 Sell 55.55 20,000 1,111,000 11/13/20